ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Associate Director, Statistical Programming at Revolution Medicines - ApplyBlast

Associate Director, Statistical Programming

Revolution Medicines

5 months ago

3.5 on Glassdoor

United States

Onsite

Full Time

Senior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

A Senior Statistical Programming Specialist at Revolution Medicines, responsible for programming support and oversight of oncology clinical trials, ensuring compliance with CDISC standards, and managing regulatory submissions.

Responsibilities

Provide SAS Programming technical support and guidance to programming team
Oversight/participation in any internal/mock or regulatory authority audits
Timeline and vendor management for deliverables, including submission-related activities
Oversee the programming support for relevant deliverables, such as Investigator Brochures, publications, US and ex-US regulatory submissions
Hands-on programming and management of in-house deliverables including but not limited to Dose Committee meetings, Board of Director meetings, Exploratory Analysis

Skills

Qualifications

BS/BA in Statistics, Mathematics, or a related field

About Revolution Medicines

revmed.com

Headquarters

Redwood City, California, United States

Company Size

201-500 employees

Founded

2014

View Profile

Revolution Medicines (RevMed) is a biopharmaceutical company dedicated to discovering, developing, and delivering novel targeted medicines for patients with cancer. Their mission focuses specifically on "revolutionizing treatment for patients with RAS‑addicted cancers" through precision-targeted therapies. The company emphasizes a science-driven, end-to-end approach from discovery to delivery. RevMed brands its team as "Revolutionaries" committed to transforming outcomes for people with RAS‑driven tumors.